<div id="readability-page-1"><div>(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet.Hutchmed China explained that the study looked at savolitinib and osimertinib in combination for the treatment of &#34;locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET amplification after disease progression on first-line EGFR tyrosine kinase inhibitor therapy&#34;.MET is a tyrosine kinase receptor that has an essential role in normal cell development, said Hutchmed China.The Hong Kong-based developer of treatments for cancer and immunological diseases said savolitinib is an oral, potent and highly selective MET TKI. It is being jointly developed by Hutchmed and Cambridge, England-based pharmaceutical company AstraZeneca PLC, and commercialised by AstraZeneca. Osimertinib is a third-generation, irreversible EGFR TKI, added Hutchmed China. The company said the study was the first randomised phase three trial that confirmed the efficacy of MET inhibition in patients with &#34;advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment&#34;. Hutchmed China said interim data from the trial led to the combination being approved in China in June last year. Shares in Hutchmed China were down 0.5% at 220.00 pence around midday on Wednesday in London. &#34;The SACHI trial, now published in The Lancet, provides compelling evidence that savolitinib combined with osimertinib can transform outcomes for patients with EGFR-mutated NSCLC with MET amplification. These findings highlight the combination's ability to address MET amplification, a critical resistance mechanism, offering clinically meaningful improvements for this challenging patient population,&#34; said Shun Lu, chief of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University, and co-leading Principal Investigator of the SACHI trial. By Christopher Ward, Alliance News reporterComments and questions to newsroom@alliancenews.comCopyright 2026 Alliance News Ltd. All Rights Reserved.</div></div>

和黃醫藥

和黃醫藥（Hutchmed China Ltd）宣佈，其 SACHI 三期肺癌試驗的結果已在《柳葉刀》（The Lancet）上發表。該試驗研究了 savolitinib 和 osimertinib 聯合治療具有 MET 擴增的晚期非小細胞肺癌的效果。這是首個確認 MET 抑制在該患者羣體中有效性的隨機三期試驗。該聯合治療於去年六月在中國獲得批准。公告發布後，和黃醫藥的股價下跌 0.5%，至 220.00 便士

和黃醫藥對《柳葉刀》上發表的肺癌試驗結果表示讚賞